Four gangliosides, GM2, GD2, GD3 and 9-0-acetyl GD3, and the high molecular weight melanoma chondroitin sulfate proteoglycan epitope (mel-CSPG) are prominent cell membrane components of melanoma that we have selected as potential targets for immunological control after active immunization. Of these, GM2 is most immunogenic, but reactivity with GM2 has been largely restricted to IgM antibodies in a pattern most consistent with GM2 acting as a T cell independent antigen. Consequently, we have screened in the mouse, a large number of newer methods for augmenting or replacing T cell help. The three most promising approaches have been selected for adjuvant clinical trials in AJCC Stage III melanoma patients: a potent new macrophage activator and B cell mitogen termed proteosomes, as adjuvant/vehicle used either alone or mixed with other adjuvants or mitogens; covalent attachment at high epitope density of ganglioside to KLH for induction of T cell help; and the use of anti-idiotypic antibodies with binding sites which are internal images of the immunogenic epitopes of GD3 and mel-CSPG. following immunization, the antibody response will be monitored with ELISAs, immune stains and assays on cultured melanoma cells, and the DTH skin test response against the immunogen and related epitopes will be measured.
Our specific aims are: 1. Identify and perfect the approaches which most effectively induce antibodies and/or DTH against at least 3 of these 5 antigens. 2. Construct and test the immunogenicity of a polyvalent vaccine based on the findings in Aim 1 and optimize it with regard to dose, route and schedule. 3. Test this demonstrably immunogenic polyvalent vaccine in a larger therapy trial in patients with measurable disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA040532-04A2
Application #
3180620
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1986-12-01
Project End
1992-04-30
Budget Start
1991-05-17
Budget End
1992-04-30
Support Year
4
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021
Tanaka, T; Yamasaki, H; Mesnil, M (2001) Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro. Int J Cancer 91:538-42
Livingston, P O (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147-66
Helling, F; Zhang, S; Shang, A et al. (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-8
Livingston, P O; Wong, G Y; Adluri, S et al. (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-44
Livingston, P O; Adluri, S; Helling, F et al. (1994) Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-80
Livingston, P O; Calves, M J; Helling, F et al. (1993) GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 11:1199-204
Ritter, G; Boosfeld, E; Adluri, R et al. (1991) Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 48:379-85
Livingston, P O (1989) Experimental and clinical studies with active specific immunotherapy. Prog Clin Biol Res 288:309-21
Livingston, P O; Ritter, G; Srivastava, P et al. (1989) Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-50